RecruitingNot ApplicableNCT06286657
Xanthohumol and Viral Infections (XL)
Xanthohumol in the Prevention of Virus-mediated Upper Respiratory Tract Infections in Humans
Sponsor
University of Vienna
Enrollment
100 participants
Start Date
Aug 1, 2023
Study Type
INTERVENTIONAL
Conditions
Summary
The aim of the present study is to determine if a regular oral supplementation of xanthohumol attenuate the severity of symptoms and duration of´viral infections.
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria2
- healthy
- BMI \>18 kg/m² or \< 28kg/m²
Exclusion Criteria8
- food intolerances
- food allergies
- chronic inflammatory diseases
- metabolic diseases
- viral or bacterial infections within the last 3 weeks of inclusion
- intake of immunosuppressive medication
- severe acute respiratory syndrome coronavirus type 2-infection in the last 4 months
- influenza infection in the "current" flu season
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
DIETARY_SUPPLEMENTXanthohumol
Participants consume twice per day a study drink which contains 0,75 mg soluble Xanthohumol for 90 days
DIETARY_SUPPLEMENTPlacebo
Participants consume twice per day a study drink which contains 0 mg soluble Xanthohumol for 90 days
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06286657